Breaking New Ground in Knee Arthritis Care
A peer-reviewed 24-month observational cohort of Arthrosamid for knee osteoarthritis, presented with the study design and limitations needed to interpret the findings.
Reviewed byProfessor Paul Lee MBBch, FRCS (Tr & Orth), PhDCartilage and joint preservation expertiseBringing Evidence to Non-Surgical Care
Knee osteoarthritis fundamentally impacts quality of life, mobility, and independence. Historically, patients faced a gap between temporary symptom relief and invasive joint replacement surgery.
London Cartilage Clinic and MSK Doctors reported a prospective observational cohort of Arthrosamid®. Our research tracked patients in routine clinical settings. It had no randomised control group, so it reports group-level associations rather than proving that treatment caused the changes.
What is Arthrosamid®?
An innovative intra-articular polyacrylamide hydrogel. It physically integrates with the synovium to provide a stable, shock-absorbing cushion.
Understanding Knee Osteoarthritis
When the protective cartilage cushioning the knee joint deteriorates, it leads to a cycle of pain, inflammation, and reduced mobility.
Persistent pain during daily movement
Severe joint stiffness after resting periods
Recurrent swelling or grinding sensations
Difficulty navigating stairs or standing
Key Findings at 24 Months
The cohort reported changes in patient-reported pain and function at group level. These findings do not predict an individual response or prove a treatment duration.
Significant Pain Reduction
Mean pain scores were lower at 24 months than at baseline. Without a control group, the study cannot show how much of that change was caused by Arthrosamid.
Restored Mobility
The Oxford Knee Score and Lysholm score improved at group level. Individual results varied, and the study did not compare Arthrosamid with another treatment.
Sustained Gains
Follow-up extended to 24 months. That is an observed study period, not a promise that benefit will last for two years or that another intervention will be avoided.
Optimal Response Profile
Subgroup observations can generate useful questions for assessment, but an uncontrolled cohort cannot supply an individual response prediction.
Read the Cohort Alongside Its Limitations
The paper reports promising group-level symptom outcomes through 24 months. It does not establish structural benefit, superiority or a guaranteed duration for an individual.